About one in three patients with advanced immune deficiency will develop disseminated MAC infection. This incidence can be reduced with prophylactic drug therapy, and established infections can be effectively treated, with improved quality of life and lengthened survival.
|Number of pages||3|
|Journal||The Medical Journal of Australia|
|Publication status||Published - 6 May 1996|